348 completed, 103 terminated, 63 recruiting, 40 active not recruiting. 615 Phase 1, 205 Phase 2.
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-11-04 | 2026-10-30 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-11-04 | 2026-10-30 |
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-10-29 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-28 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
| QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 | 2026-08-07 |
| Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies Thiotepa, Fludarabine, Busulfan - Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 1 | Recruiting | Sawa Ito, MD | 48 | 2026-07-27 | 2026-08-18 |
| Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis Ropeginterferon - JAK2 Mutation | Phase 1 | Recruiting | Brigham and Women's Hospital | 12 | 2026-07-24 | 2026-07-28 |
| TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT) | Phase 1 | Recruiting | Stanford University | 50 | 2026-07-21 | 2026-08-17 |
| Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets TQ05105 tablets, Rabeprazole sodium enteric-coated tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 17 | 2026-07-20 | 2026-07-27 |
| A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis rebecsinib - Secondary AML, Myelofibrosis | Phase 1 | Recruiting | Aspera Biomedicines, Inc. | 28 | 2026-05-21 | 2026-07-20 |
| Therapeutic RSK1 Targeting in Myeloid Malignancies PMD-026 - Myeloid Malignancy | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2026-05-20 | 2026-10-21 |
| Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers ZE74-0282 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Not yet recruiting | Eilean Therapeutics | 60 | 2026-05-15 | 2026-04-14 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-10-30 |
Showing 20 of 615. Sign in to see all of them.
Leukemia, Myeloid, Acute (297) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (249) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (230) · Myelodysplastic Syndromes (210) · Primary Myelofibrosis (198) · Leukemia (185) · Blast Crisis (148) · Leukemia, Lymphocytic, Chronic, B-Cell (132) · Leukemia, Myelomonocytic, Chronic (121) · Lymphoma, Non-Hodgkin (112) · Leukemia, Myeloid, Chronic-Phase (108) · Multiple Myeloma (106) · Congenital Abnormalities (101) · Leukemia, Myeloid, Accelerated Phase (99)
Hemic and Lymphatic Diseases (615) · Bone Marrow Diseases (607) · Hematologic Diseases (602) · Neoplasms (513) · Neoplasms by Histologic Type (494) · Leukemia, Myeloid (469) · Pathologic Processes (437) · Pathological Conditions, Signs and Symptoms (437) · Disease Attributes (435) · Chronic Disease (430) · Leukemia (305) · Immune System Diseases (295) · Immunoproliferative Disorders (293) · Lymphatic Diseases (291)
ruxolitinib (51) · Cytarabine (49) · fludarabine phosphate (47) · Cyclophosphamide (46) · Imatinib Mesylate (36) · Peripheral Blood Stem Cell Transplantation (33) · Filgrastim (32) · Tacrolimus (28) · fludarabine (28) · Azacitidine (27) · Busulfan (27) · Mycophenolic Acid (26) · Dasatinib (24) · Whole-Body Irradiation (22) · Cyclosporine (21)
National Cancer Institute (NCI) (60) · M.D. Anderson Cancer Center (41) · Fred Hutchinson Cancer Center (24) · Novartis Pharmaceuticals (22) · Incyte Corporation (14) · Memorial Sloan Kettering Cancer Center (13) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (13) · Bristol-Myers Squibb (12) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (12) · Masonic Cancer Center, University of Minnesota (11) · City of Hope Medical Center (10) · Roswell Park Cancer Institute (8) · Case Comprehensive Cancer Center (7) · National Heart, Lung, and Blood Institute (NHLBI) (7) · John Mascarenhas (6)
United States (484) · Italy (48) · Germany (46) · Canada (43) · France (43) · Australia (31) · Spain (31) · United Kingdom (30) · China (29) · South Korea (22) · Japan (19) · Netherlands (19) · Belgium (16) · Poland (12) · Israel (10)
Jorge Cortes, MD (9) · Ronald Hoffman, MD (7) · John Mascarenhas, MD (6) · Ayalew Tefferi, MD (5) · Brenda Sandmaier (4) · Jorge Cortes (4) · Judith E. Karp, MD (4) · Roger Strair, MD, PhD (4) · Ann E. Woolfrey, MD (3)
PMID 16775234, PMID 31527168, PMID 32499241, PMID 34699069, PMID 11331327, PMID 11585760, PMID 12114413, PMID 12171484, PMID 12750167, PMID 15231574, PMID 15514371, PMID 15570084, PMID 15958631, PMID 16275934, PMID 16278404, PMID 16670265, PMID 16775235, PMID 16990776, PMID 17151364, PMID 17562873, PMID 17640728, PMID 17715389, PMID 17875804, PMID 17971589, PMID 18048643, PMID 18172005, PMID 18327587, PMID 18571721, PMID 18974373, PMID 19010875, PMID 19029442, PMID 19075272, PMID 19092853, PMID 19109557, PMID 19139736, PMID 19179301, PMID 19503090, PMID 19557623, PMID 20015886, PMID 20460644, PMID 20511167, PMID 20563869, PMID 20843246, PMID 20858843, PMID 20860038, PMID 20952518, PMID 20952687, PMID 21098399, PMID 21145590, PMID 21239698
P30CA006973 (11), P30CA015704 (10), P30CA016672 (8), U01CA062461 (8), U01CA070095 (8), 2023 (6), P30CA033572 (6), U01CA097452 (5), 2018 (4), P01CA018029 (4), P01CA108671 (4), P30CA043703 (4), P30CA072720 (4), U01CA062491 (4), U01CA062505 (4)